The global HIV antivirals market is set for a period of robust growth, with a new forecast predicting its value will climb ...

Patients with HIV who are resistant to all four antiretroviral drug classes face a higher risk for death than those who are ...

Stocks saw their best week since June, with a rally in big tech driving the Nasdaq 100 to all-time highs. Also buoying ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

The yield on 10-year Treasuries rose three basis points to 4.28%. The dollar barely budged. Oil resumed gains after a brief ...

The S&P 500 climbed Friday as tech stocks rallied, nearing its all-time closing high. Key Takeaways. The S&P 500 added 0.8% on Friday, Au ...

Stocks in the health-care industry rose as markets grew more confident that U.S. borrowing costs will fall, while companies in the sector pleased investors in their quarterly reports. Gilead Sciences ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year ...

Gilead stock briefly broke out Friday after the biotech company beat second-quarter forecasts amid its newest launch in HIV ...

Wall Street is ending the week on a positive note, with stocks set for all-time highs amid solid corporate results and hopes ...

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed ...